Physician profile
Thomas A Wolf
NPI 1659305506
$5,724.77
in general payments reported to CMS, 2019-2025
54 companies · $781 in 2025
The $781 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $314 · 2021: $456 · 2022: $897 · 2023: $1,876 · 2024: $994 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,709 · Travel and Lodging: $880 · Education: $62.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,708.78 |
| Travel and Lodging | $879.76 |
| Education | $62.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim International Gmbh | $1,254.76 | 2023 | |
| Abbvie INC. | $787.01 | 2019-2025 | Vraylar, Qulipta, Viberzi |
| Amgen INC. | $417.71 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $369.36 | 2019-2025 | Synjardy, Tradjenta, Jardiance |
| Pfizer INC. | $316.81 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $292.31 | 2020-2025 | Airsupra |
| Lilly USA, LLC | $212.55 | 2021-2025 | Jardiance, Mounjaro, Kisunla |
| Janssen Pharmaceuticals, INC | $210.12 | 2019-2022 | |
| Novo Nordisk INC | $183.60 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Mannkind Corporation | $133.52 | 2023-2025 | Afrezza |
| Lexicon Pharmaceuticals, INC. | $132.44 | 2024 | Inpefa |
| Amarin Pharma, INC. | $126.97 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $121.54 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $94.99 | 2022-2025 | Rexulti |
| Allergan, INC. | $89.96 | 2019-2020 |
Show all 48 companies
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.